You are here:Home-ADCs and PROTACs-PROTAC-ACBI3
ACBI3

Chemical Structure : ACBI3

CAS No.: 2938169-76-5

ACBI3 (pan-KRAS degrader ACBI3)

Catalog No.: PC-21662Not For Human Use, Lab Use Only.

ACBI3 is a selective, potent and in vivo active pan-KRAS PROTAC degrader, potently degrades 13 out of 17 of the most prevalent oncogenic KRAS alleles (DC50=3.9 nM in GP2d cells).

Packing Price Stock Quantity
2 mg $398 In stock
5 mg $598 In stock
10 mg Get quote
25 mg Get quote
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

ACBI3 is a selective, potent and in vivo active pan-KRAS PROTAC degrader, potently degrades 13 out of 17 of the most prevalent oncogenic KRAS alleles (DC50=3.9 nM in GP2d cells).
ACBI3 exhibits potent intracellular VHL engagement, ternary complex formation and ubiquitination translating into overall E3-ligase dependent cellular degradation potency.
ACBI3 is broadly active on cancer cell lines bearing KRAS mutations vs KRAS WT cell lines (IC50, 478 nM vs 8.3 µM, respectively).
ACBI3 (30 mg/kg, daily s.c.) resulted in pronounced tumour regressions with a tumour growth inhibition of 127% in GP2d tumour bearing mice.
ACBI3 effectively acts on the majority of KRAS mutants with high prevalence in cancer patients, and as a result potently inhibit proliferation in KRAS mutant cell lines covering a wide range of tumour types.

Physicochemical Properties

M.Wt 1019.26
Formula C50H62N14O6S2
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

(2S,4R)-1-((S)-2-(4-(4-((S)-4-(4-(5-((S)-2-amino-3-cyano-4-methyl-4,5,6,7-tetrahydrobenzo[b]thiophen-4-yl)-1,2,4-oxadiazol-3-yl)pyrimidin-2-yl)-3-methyl-1,4-diazepan-1-yl)butoxy)-1H-1,2,3-triazol-1-yl)-3-methylbutanoyl)-4-hydroxy-N-((R)-2-hydroxy-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

References

1. Johannes Popow, et al. Targeting cancer with small molecule pan-KRAS degraders. bioRxiv October 26, 2023.

2. Patent WO2023099620 A1.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: